Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | Identifying residual LSCs that may evade standard MRD monitoring & lead to relapse in AML

Raffaele Palmieri, MD, University of Rome “Tor Vergata”, Rome, Italy, comments on the importance of monitoring specific subsets of cells in the leukemic stem cell (LSC) compartment that may evade standard measurable residual disease (MRD) monitoring and lead to relapse in patients with acute myeloid leukemia (AML). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.